BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

AMGN upcoming catalysts

Amgen: 5 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (3 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 17 readout(s) and 3 FDA event(s). Subscribe to AMGN (.ics).

Drugs: Anvumetostat, Dazodalibep, Docetaxel, ABP 234, Pembrolizumab, AMG 732, Maridebart Cafraglutide, sotorasib, Midazolam, Nivolumab

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-30 est.P1/P2Amgen AMGNNCT05094336 A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)Advanced MTAP-null Solid Tumorsactive not recruiting329
2026-12-14 est.P3Amgen AMGNNCT06430866 Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)active not recruiting163
2027-01-06 est.P1/P2Amgen AMGNNCT06401044 A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye DiseaseThyroid Eye Diseaseactive not recruiting94
2027-01-21 est.P3Amgen AMGNNCT06858839 Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightObesityactive not recruiting3853
2027-01-21 est.P3Amgen AMGNNCT06858878 Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightType 2 Diabetes Mellitus (T2DM), Obesity, Overweightactive not recruiting1105

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-10-22FDA approvalapprovedAMGEN INC AMGNPAVBLUApproved 2026-10-22: PAVBLU (BLA761298 ORIG2)
2026-10-09FDA approvalapprovedAMGEN INC AMGNREPATHAApproved 2026-10-09: REPATHA (BLA125522 SUPPL47)
2025-11-19FDA approvalapprovedAMGEN INC AMGNIMDELLTRAApproved 2025-11-19: IMDELLTRA (BLA761344 SUPPL1)

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-31 est.P2Amgen AMGNNCT06593522 A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)MTAP-deleted NSCLCactive not recruiting61
2026-10-22 est.P3Amgen AMGNNCT06245408 A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom StateSjögren's Syndrome (SS)active not recruiting434
2026-08-12P3Amgen AMGNNCT06088199 A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque PsoriasisPlaque Psoriasiscompleted51
2026-07-23P3Amgen AMGNNCT06104124 A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease ActivitySjogren's Syndromecompleted651
2026-07-01P3Amgen AMGNNCT05882877 A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AAtopic Dermatitisterminated2621
2026-05-29P1/P2Amgen AMGNNCT03600883 A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodKRAS p.G12C Mutant Advanced Solid Tumorscompleted713
2026-05-14P2Amgen AMGNNCT06376045 A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe AsthmaAsthmaterminated317
2026-04-28P2Amgen AMGNNCT06312020 A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's SyndromeSjogren's Syndrometerminated209
2026-04-17P3Amgen AMGNNCT06527404 A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo NodularisPrurigo Nodularisterminated469
2026-03-10P3Amgen AMGNNCT03937154 Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast CancerChemotherapy-induced Thrombocytopeniaactive not recruiting145
2026-02-25P1/P2Amgen AMGNNCT05975073 A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid TumorsMTAP-null Non-Small-Cell Lung Cancer; MTAP-null Solid Tumorscompleted53
2026-01-28P1/P2Amgen AMGNNCT05325866 A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionSolid Tumorsterminated260
2026-01-06P2Amgen AMGNNCT06054113 Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)B Precursor Acute Lymphoblastic Leukemia; Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemactive not recruiting18
2025-12-23P3Amgen AMGNNCT06248619 A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active ThyroThyroid Eye Diseaseactive not recruiting89
2025-11-21P1/P2Amgen AMGNNCT05322577 A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal JuncGastric Cancer; Gastroesophageal Junction Cancerterminated72
2025-11-20P3Amgen AMGNNCT05565560 A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque PsoriasisPlaque Psoriasiscompleted21
2025-11-19P3Amgen AMGNNCT03836040 Efficacy and Safety of Erenumab in Pediatric Participants With Episodic MigraineMigraineactive not recruiting457

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.